The Indian Patent Office has rejected the patent application submitted by the American company Global Alliance for TB Drug Development concerning the drug BPaL—a vital tuberculosis therapy. The basis for this decision was the lack of novelty and inventive step.
Healthcare experts note that this decision may open up opportunities for local drug manufacturers to bring more affordable generic versions of this drug to the market in India and other countries with a high disease burden.